Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Articles|June 18, 2020
Pharmacy Hero: Pharmacist Works at Pharmacy, Testing Site During COVID-19 Pandemic
Today, we’re celebrating Morgan Adams, PharmD, a pharmacist with CVS in Connecticut.
Advertisement
Today, we’re celebrating Morgan Adams, PharmD, a pharmacist with CVS in Connecticut. In addition to working in a busy retail store, Adams has also volunteered to work at a drive-through testing site for coronavirus disease 2019 (COVID-19).
“She is going above and beyond during these trying times,” said Kristen Masood, PharmD.
Pharmacy Times® wants to celebrate the amazing pharmacy staff members who are on the front lines every day. Nominate someone in your pharmacy by emailing
Advertisement
Related to this article
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5